Search results
FTSE 100 Live 20 May: Early blue-chip gains fade, oil rises, Ryanair hires Amber Rudd
Evening Standard via Yahoo Finance· 2 hours agoThe FTSE 100 shrugged off geopolitical concerns in early trading today, but its gains have faded in...
New virus variants threaten a summer COVID-19 wave, but experts say risk remains uncertain
KSL Salt Lake City· 4 days agoCOVID-19 levels are about the lowest they've ever been in the United States, but another new crop of...
5 Things to Know: COVID-19 Vaccines for Immunocompromised People
Medscape· 5 days agoCDC experts share what clinicians should know about COVID-19 prevention in immunocompromised...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Digital Journal· 7 days ago...terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19),...
Trending tickers: Gold, Ryanair, Nvidia and AstraZeneca
Yahoo Finance UK· 22 hours agoAstraZeneca (AZN.L) Shares in the drugmaker were lower in London after it announce an $1.5bn...
What’s Going On With The New COVID FLiRT Variants?
IFLScience· 5 days agoRecently, we reported on the new family of COVID-19 variants that looked set to start overtaking the pack to become the most widespread. Now,...
AstraZeneca Covid vax linked to another rare fatal blood clotting disorder
Investing.com· 5 days agoNew Delhi, May 16 (IANS) British-Swedish pharma giant AstraZeneca's Covid-19 vaccine, made in...
Long Dismissed, Chronic Lyme Is Finally in the Spotlight
Time via AOL· 5 days agoFalse negatives are common, especially when people are tested early in their infections, since it...
Chronic Lyme Disease: Why COVID May Spark Better Tests and Treatment
Well and Good· 6 days agoPeople with chronic Lyme disease (or PTLDS) are understudied and have limited treatment options, but...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 7 days agoDuring the March quarter, the U.S. government handed back 5.1 million courses...on new drug...